Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connor Johnson

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Blood Advances|January 24, 2022
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort studyJ Erika Haydu, Jenny S Maron, Robert A Redd, et al.
Blood Neoplasia|December 22, 2025
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphomaJ Erika Haydu, Matthew M Lei, Robert A Redd, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Nature Medicine|January 9, 2023
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndromeErin M Parry, Ignaty Leshchiner, Romain Guièze, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Blood Advances|January 24, 2022
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort studyJ Erika Haydu, Jenny S Maron, Robert A Redd, et al.
Blood Neoplasia|December 22, 2025
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphomaJ Erika Haydu, Matthew M Lei, Robert A Redd, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Nature Medicine|January 9, 2023
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndromeErin M Parry, Ignaty Leshchiner, Romain Guièze, et al.
Pageof 11